Importantly, a sustained clinical response was observed in one patient with metastatic cSCC harbouring mutations (including the PIK3CA P471L mutation) upon treatment with the mTOR inhibitor temsirolimus [105]. The gene discussed is PIK3CA; the disease is skin squamous cell carcinoma.